MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41598-017-11893-8

Медицинская библиотека · Scientific reports · 2017

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.

Manasa Justen, Varghese Vici, Pond Sergei L Kosakovsky, Rhee Soo-Yon, Tzou Philip L, Fessel W Jeffrey, Jang Karen S, White Elizabeth, Rögnvaldsson Thorsteinn, Katzenstein David A, Shafer Robert W

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp41-CD) reduce protease inhibitor (PI) susceptibility without PI-resistance mutations in protease. However, no gag and gp41-CD mutations definitively responsible for reduced PI susceptibility have been identified in individuals with virological failure (VF) while receiving a boosted PI (PI/r)-containing regimen. To identify gag and gp41 mutations under selective PI pressure, we sequenced gag and/or gp41 in 61 individuals with VF on a PI/r (n = 40) or NNRTI (n = 20) containing regimen. We quantified nonsynonymous and synonymous changes in both genes and identified sites exhibiting signal for directional or diversifying selection. We also used published gag and gp41 polymorphism data to highlight mutations displaying a high selection index, defined as changing from a conserved to an uncommon amino acid. Many amino acid mutations developed in gag and in gp41-CD in both the PI- and NNRTI-treated groups. However, in neither gene, were there discernable differences between the two groups in overall numbers of mutations, mutations displaying evidence of diversifying or directional selection, or mutations with a high selection index. If gag and/or gp41 encode PI-resistance mutations, they may not be confined to consistent mutations at a few sites.

Для цитирования: Manasa Justen, Varghese Vici, Pond Sergei L Kosakovsky, Rhee Soo-Yon, Tzou Philip L, Fessel W Jeffrey, Jang Karen S, White Elizabeth, Rögnvaldsson Thorsteinn, Katzenstein David A, Shafer Robert W. Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.. Scientific reports. 2017. DOI: 10.1038/s41598-017-11893-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.